dr. rugo on the results of the keynote-522 trial in tnbc
Published 4 years ago • 497 plays • Length 1:43Download video MP4
Download video MP3
Similar videos
-
6:01
immunotherapy for triple-negative breast cancer
-
1:57
dr. rugo on results of oral paclitaxel with encequidar in metastatic breast cancer
-
4:20
keynote-522: 5-year follow-up of pembrolizumab in triple-negative breast cancer
-
3:09
keynote-522: neoadjuvant and adjuvant pembrolizumab for early tnbc
-
0:53
keynote-522 demonstrates potential for immunotherapy in triple-negative breast cancer
-
0:59
expert discusses the value of combination treatment in tnbc treatment
-
0:50
update on keynote 522, the current standard of care for triple negative breast cancer.
-
2:06
dr. schmid on the design and findings of the keynote-173 trial in tnbc
-
4:53
chemoimmunotherapy in tnbc: the keynote-355 trial
-
11:50
triple negative breast cancer
-
1:11
dr. rugo on the significance of the monarch i trial for breast cancer
-
1:50
dr. rugo discusses immunotherapy in tnbc
-
1:39
dr. rugo on takeaways from the impassion130 trial in tnbc
-
9:02
phase 3 keynote-522 results: pembro/chemo neoadjuvant, pembro adjuvant in early tnbc
-
4:20
keynote 522: pembrolizumab as neoadjuvant treatment for early tnbc
-
21:00
precision medicine in metastatic triple negative breast cancer
-
11:53
new developments in triple-negative breast cancer therapies - medpage today
-
0:59
dr. bardia on the results of the ascent trial in previously treated metastatic tnbc
-
1:16
dr. tolaney on platinum-based therapy in neoadjuvant setting of tnbc